Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

Warm Autoimmune Hemolytic Anemia Clinical Trial

Official title:
An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

Status Completed

Clinical Trial Summary

This study is to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of APL-2 in subjects with warm Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03226678
Study type	Interventional
Source	Apellis Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	August 31, 2017
Completion date	September 12, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05786573` - A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)	Phase 3
Withdrawn	`NCT03965624` - Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia	Phase 2
Recruiting	`NCT05922839` - Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA	Phase 2
Completed	`NCT01181154` - Rituximab in Auto-Immune Hemolytic Anemia	Phase 3
Recruiting	`NCT05925023` - Sirolimus in the Treatment of Refractory/Relapsed wAIHA	Phase 2
Recruiting	`NCT05757570` - An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias	Phase 1/Phase 2
Withdrawn	`NCT04256148` - ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia	Phase 2
Terminated	`NCT03075878` - A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)	Phase 1/Phase 2
Withdrawn	`NCT04956276` - Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia	Phase 2
Recruiting	`NCT04119050` - Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia	Phase 2/Phase 3
Terminated	`NCT04253236` - To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).	Phase 2
Temporarily not available	`NCT05221619` - Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)